Rewiring dendritic cell function with CLEC9A and DEC205 CARs
Abstract Dendritic cells (DCs) are central orchestrators of anti-tumor immunity, yet their therapeutic utility has been limited by dysfunction and insufficient activation within solid tumors. Here, we report chimeric antigen receptor-engineered DCs (CAR-DCs) that potently prime T cells and reprogram the tumor microenvironment. We identify the intracellular domains of CLEC9A or DEC205 as essential for functional CAR-DC activity, enabling enhanced antigen uptake, cross-presentation, and robust cytokine production that drive strong T cell expansion and effector differentiation. Mechanistically, CARs incorporating CLEC9A or DEC205 intracellular domains triggered SYK phosphorylation and downstream signaling pathways. In both murine and humanized models, CAR-DC therapy suppressed tumor growth and promoted expansion of tumor-reactive T cells. These findings establish CAR-DCs as a scalable and clinically translatable platform for next-generation solid tumor immunotherapy.
Authors
- Mikäel J. Pittet (ORCID: https://orcid.org/0000-0002-2060-4691)
- Congyi Niu
- Xiaoqiu Dai (ORCID: https://orcid.org/0000-0001-5867-417X)
- Sudan He (ORCID: https://orcid.org/0000-0002-0846-1210)
- H Zhang
- Yingxi Xu (ORCID: https://orcid.org/0000-0002-0056-7440)
- Chen Wang (ORCID: https://orcid.org/0000-0003-2271-5587)
- Lianjun Zhang (ORCID: https://orcid.org/0000-0001-9448-7718)
- Peng Lin (ORCID: https://orcid.org/0000-0001-5634-6308)
- He Gao
- Xiaowen Tang
- Hui Wang
- Sudan He
- Peng Lin
- Yunju Ma
- Zhen Xiao
Institutions
- University of Geneva (CH)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- University Hospital of Geneva (CH)
- Ludwig Cancer Research (CH)
- Suzhou Institute of Systems Medicine (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- Swiss Cancer Center Léman (CH)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Nature Immunology
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1038/s41590-026-02711-3
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Science Foundation
- Ludwig Institute for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Hyderabad Eye Research Foundation
- Hôpitaux Universitaires de Genève
- Fondation ISREC
- Basic Research Program of Jiangsu Province
- National Key Research and Development Program of China